OTC · HSTC
HST Global, Inc.
$0.70$0.00 (0.0%)
HST Global, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
Loading market information…
OTC · ARDS · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aridis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aridis Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$0.60. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aridis Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin. Also in their pipeline is AR-320, another fully human IgG1 monoclonal antibody designed to target S. aureus alpha toxin, aiming to treat infections stemming from both methicillin-resistant (MRSA) and methicillin-susceptible S. aureus. The company's developmental efforts extend to AR-105, a fully human IgG1 mAb in Phase II trials, which is being developed to combat the gram-negative bacterium P. aeruginosa. Furthermore, AR-101, a human IgM mAb, is undergoing Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) specifically linked to P. aeruginosa serotype O11. In earlier stages, AR-401 is in preclinical development to address infections caused by Acinetobacter baumannii, and AR-201, a fully human IgG1 mAb, is in a preclinical program targeting respiratory syncytial virus. AR-501, an anti-infective therapy, is currently in Phase I/IIa clinical trials for managing chronic lung infections in patients with cystic fibrosis. Additionally, Aridis is developing AR-712 and AR-701, a combination of two fully human IgG1 mAbs, which is in Phase I/II clinical trials for treating mild to moderate COVID-19 in non-hospitalized individuals. Aridis Pharmaceuticals, Inc. was established in 2003 and is headquartered in Los Gatos, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 16, 2022 |
| -$0.45-650.0% vs estimate |
| $300.00K-97.13% vs estimate |
| Q1 2022 | May 16, 2022 | -$0.44+13.73% vs estimate | $1.19M-40.65% vs estimate |
|---|
| Q4 2021 | Mar 31, 2022 | -$0.92-124.39% vs estimate | $570.00K-68.33% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.70$0.00 (0.0%)
HST Global, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
€0.70-€0.04 (-4.86%)
Theraclion S.A.’s quoted price sits in the upper half of its reported 52-week range, 24.3% below the high.
$0.00$0.00 (0.0%)
Life Stem Genetics Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.00$0.00 (0.0%)
Biostax Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
Trevena, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.26% below the high.
$0.00$0.00 (0.0%)
Infinity Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.15% below the high.
$0.00$0.00 (0.0%)
Statera Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.62% below the high.
$0.00$0.00 (0.0%)
iCoreConnect Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.97% below the high.
